Douglas Kling - NewAmsterdam Pharma Chief Officer
| NAMS Stock | 23.87 0.20 0.83% |
Executive
Douglas Kling is Chief Officer of NewAmsterdam Pharma
| Age | 52 |
| Address | Gooimeer 2-35, Naarden, Netherlands, 1411 DC |
| Phone | 31 35 206 2971 |
| Web | https://www.newamsterdampharma.com |
Douglas Kling Latest Insider Activity
Tracking and analyzing the buying and selling activities of Douglas Kling against NewAmsterdam Pharma stock is an integral part of due diligence when investing in NewAmsterdam Pharma. Douglas Kling insider activity provides valuable insight into whether NewAmsterdam Pharma is net buyers or sellers over its current business cycle. Note, NewAmsterdam Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell NewAmsterdam Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Douglas Kling few days ago Disposition of 100000 shares by Douglas Kling of NewAmsterdam Pharma at 23.16 subject to Rule 16b-3 | ||
Douglas Kling over two weeks ago Disposition of 8914 shares by Douglas Kling of NewAmsterdam Pharma at 21.33 subject to Rule 16b-3 | ||
Douglas Kling over a month ago Disposition of 9218 shares by Douglas Kling of NewAmsterdam Pharma at 19.23 subject to Rule 16b-3 | ||
Douglas Kling over a month ago Disposition of 90782 shares by Douglas Kling of NewAmsterdam Pharma at 19.54 subject to Rule 16b-3 |
NewAmsterdam Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1819) % which means that it has lost $0.1819 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.462) %, meaning that it created substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to gain to -0.22 in 2025. At this time, NewAmsterdam Pharma's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 60.1 M in 2025, whereas Other Assets are likely to drop slightly above 23.9 K in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tobin Schilke | Crinetics Pharmaceuticals | 50 | |
| Christopher Sarchi | Replimune Group | 56 | |
| Mary CPA | Cullinan Oncology LLC | 61 | |
| MBA MA | Replimune Group | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 62 | |
| Maria Dobek | Janux Therapeutics | 35 | |
| Michelle MD | PepGen | 49 | |
| Mary DeLena | PepGen | N/A | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Eric LLM | Inventiva Sa | 51 | |
| Jose CPA | Mineralys Therapeutics, Common | 35 | |
| Renate Gloggner | Molecular Partners AG | 55 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Zachariah Mciver | Janux Therapeutics | N/A | |
| Nina Aragam | Replimune Group | N/A | |
| Alice PharmD | Inventiva Sa | 54 | |
| CPA CFA | Janux Therapeutics | 48 | |
| Dilip Kodira | PureTech Health PLC | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| James Pennington | Janux Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.18 |
NewAmsterdam Pharma Leadership Team
Elected by the shareholders, the NewAmsterdam Pharma's board of directors comprises two types of representatives: NewAmsterdam Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NewAmsterdam. The board's role is to monitor NewAmsterdam Pharma's management team and ensure that shareholders' interests are well served. NewAmsterdam Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NewAmsterdam Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louise Kooij, Treasurer, CFO | ||
| Jim Jacobson, Chief Secretary | ||
| Annie Neild, VP Affairs | ||
| FESC MD, Chief Founder | ||
| Marc MD, Chief Officer | ||
| MSc MBA, Chief Officer | ||
| Lina Gugucheva, Chief Officer | ||
| Sheng Cui, Chief Officer | ||
| Douglas Kling, Chief Officer | ||
| FACC Facp, President CEO | ||
| Bob Rambo, Executive Marketing | ||
| MBA Jones, Chief Officer | ||
| Maryellen McQuade, Chief Officer | ||
| FACC Facc, President, CEO | ||
| Mayur Somaiya, Chief Officer | ||
| Matthew Philippe, Executive Relations |
NewAmsterdam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NewAmsterdam Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 109.82 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 99.33 % | ||||
| Number Of Shares Shorted | 2.91 M | ||||
| Price To Book | 3.42 X | ||||
| Price To Sales | 58.01 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.